Personalis, Inc. (PSNL)
Healthcare • Diagnostics & Research
StockNasdaqGMUnited StatesUS71535D1063
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Personalis, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.23 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.25 | -0.32 | -26.3% | Miss |
| 04 Aug 2026 16:00 | -0.28 | -0.30 | -9.1% | Miss |
| 07 May 2026 16:00 | -0.28 | -0.29 | -2.7% | Miss |
| 26 Feb 2026 16:00 | -0.28 | -0.26 | +8.8% | Beat |
| 04 Nov 2025 16:00 | -0.27 | -0.24 | +12.5% | Beat |
| 05 Aug 2025 16:00 | -0.24 | -0.23 | +5.9% | Beat |
| 06 May 2025 16:00 | -0.25 | -0.18 | +28.0% | Beat |
| 27 Feb 2025 16:00 | -0.28 | -0.23 | +19.0% | Beat |
| 06 Nov 2024 16:00 | -0.34 | -0.64 | -89.4% | Miss |
| 07 Aug 2024 16:00 | -0.38 | -0.24 | +36.2% | Beat |
| 08 May 2024 16:00 | -0.38 | -0.26 | +32.3% | Beat |
| 28 Feb 2024 16:00 | -0.48 | -0.54 | -11.7% | Miss |
| 07 Nov 2023 16:00 | -0.52 | -0.48 | +7.0% | Beat |
| 08 Aug 2023 16:00 | -0.54 | -0.50 | +6.8% | Beat |
| 03 May 2023 16:00 | -0.58 | -0.61 | -4.8% | Miss |
| 23 Feb 2023 16:00 | -0.64 | -0.67 | -4.3% | Miss |
| 02 Nov 2022 16:00 | -0.63 | -0.58 | +8.3% | Beat |
| 03 Aug 2022 16:00 | -0.58 | -0.60 | -2.9% | Miss |
| 04 May 2022 16:00 | -0.58 | -0.63 | -9.1% | Miss |
| 24 Feb 2022 16:00 | -0.50 | -0.45 | +9.3% | Beat |
| 04 Nov 2021 07:00 | -0.42 | -0.40 | +5.6% | Beat |
| 04 Aug 2021 16:00 | -0.39 | -0.34 | +12.4% | Beat |
| 05 May 2021 16:00 | -0.36 | -0.29 | +18.9% | Beat |
| 25 Feb 2021 16:00 | -0.30 | -0.34 | -12.1% | Miss |
| 05 Nov 2020 16:00 | -0.28 | -0.27 | +2.6% | Beat |
| 06 Aug 2020 16:00 | -0.34 | -0.29 | +14.7% | Beat |
| 07 May 2020 17:00 | -0.26 | -0.29 | -10.1% | Miss |
| 25 Mar 2020 16:00 | -0.25 | -0.04 | +84.0% | Beat |
| 13 Nov 2019 16:00 | -0.25 | -0.17 | +32.8% | Beat |
| 13 Aug 2019 16:00 | -0.26 | -0.19 | +27.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 69.6M | -17.7% | -81.3M | -116.7% | -0.91 | +33.6% | -79.5M |
| 2024 | 84.6M | +15.2% | -81.3M | -96.1% | -1.37 | +39.1% | -46.8M |
| 2023 | 73.5M | +13.0% | -108.3M | -147.4% | -2.25 | +9.3% | -67.2M |
| 2022 | 65M | — | -113.3M | -174.2% | -2.48 | — | -120.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 15.92 | 16.07 | 15.52 | 15.69 | -0.82% | 22,656,789 | |
| Oct 2026 | 16.22 | 16.58 | 15.51 | 15.82 | -2.83% | 51,513,800 | |
| Sep 2026 | 17.00 | 17.38 | 15.92 | 16.28 | -2.98% | 45,814,700 | |
| Aug 2026 | 12.44 | 18.89 | 12.35 | 16.78 | +32.54% | 77,344,900 | |
| Jul 2026 | 13.16 | 16.39 | 11.52 | 12.66 | -5.52% | 112,745,500 | |
| Jun 2026 | 10.99 | 14.07 | 9.08 | 13.40 | +17.54% | 76,233,400 | |
| May 2026 | 5.54 | 11.85 | 5.35 | 11.40 | +106.52% | 54,580,300 | |
| Apr 2026 | 6.56 | 7.04 | 4.96 | 5.52 | -13.34% | 38,338,800 | |
| Mar 2026 | 8.26 | 9.39 | 6.04 | 6.37 | -29.69% | 37,244,300 | |
| Feb 2026 | 9.38 | 9.79 | 7.27 | 9.06 | -3.31% | 25,123,400 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega (opens in a new tab) 09 Nov 2026 15:40
- Did Wider Losses Just Shift Personalis (PSNL) Stock Investment Narrative? (opens in a new tab) Simply Wall St. · 07 Nov 2026 07:12
- Personalis: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 04 Nov 2026 21:28
- Personalis Reports Third Quarter Results (opens in a new tab) 04 Nov 2026 21:01
- Personalis Q3 EPS $(0.32) Misses $(0.25) Estimate, Sales $25.596M Beat $21.850M Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:24
- Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years (opens in a new tab) Simply Wall St. · 20 Oct 2026 07:11
- The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. (opens in a new tab) The Wall Street Journal · 04 Sep 2026 10:30
- Piper Sandler Lifts Tempus AI to Overweight at $76 (opens in a new tab) GuruFocus.com · 01 Sep 2026 14:45
- Tempus AI shares rise 2.7% following analyst actions (opens in a new tab) InvestorsHub · 01 Sep 2026 14:36
- Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? (opens in a new tab) Insider Monkey · 27 Aug 2026 23:01
- Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next. (opens in a new tab) Barchart · 26 Aug 2026 16:50
- Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed (opens in a new tab) Simply Wall St. · 22 Aug 2026 09:08
- Has Tempus AI (TEM) Run Too Far Ahead Of Its Valuation Narrative? (opens in a new tab) Simply Wall St. · 22 Aug 2026 05:18
- TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight (opens in a new tab) Stocktwits · 20 Aug 2026 18:22
- TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial (opens in a new tab) Stocktwits · 19 Aug 2026 18:49
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 15.86 USD
- Market cap
- 1.7B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow PSNL and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.